Evidence map›Paper›PMID 40589566›Full record

ArticleMolecular therapy. Oncology2025

K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies.

Nienke Visser, Macarena González-Corrales, Jimena Álvarez-Freile, Maurien G Pruis, Lena Rockstein, Harm Jan Lourens, Jan Jacob Schuringa, Tom van Meerten, Gerwin Huls, Edwin Bremer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nienke VisserDepartment of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, the Netherlands.
Macarena González-CorralesDepartment of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, the Netherlands.
Jimena Álvarez-FreileDepartment of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, the Netherlands.
Maurien G PruisDepartment of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, the Netherlands.
Lena RocksteinDepartment of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, the Netherlands.
Harm Jan LourensDepartment of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, the Netherlands.
Jan Jacob SchuringaDepartment of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, the Netherlands.
Tom van MeertenDepartment of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, the Netherlands.
Gerwin HulsDepartment of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, the Netherlands.
Edwin BremerDepartment of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor (CAR)-based therapy is of interest for relapsed or refractory (r/r) T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphomas. A prominent target antigen for this is the receptor CD7, which is expressed in ∼95% of T-ALL, ∼50% of peripheral T cell lymphomas, as well as 10% of acute myeloid leukemias. Here, we preclinically evaluated and compared CD7-targeted ligand K12-based CAR-T to an scFvCD7-based CAR-T construct. K12 CAR-T cells produced significantly higher interferon gamma (IFN-γ) after CD7 activation compared to scFv-CD7 CAR-T cells. Similarly, in a Jurkat

Indexed as

AMLCD7-positive malignancyK12ligand-based CAR-TMT: Regular IssueT-ALL

Identifiers

PMID40589566
PMCPMC12208613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.